Disclosures for "Early Targeted C1q Inhibition With Tanruprubart Improves Functional Recovery in Guillain-Barré Syndrome: Results From a Phase Three Study"
-
Dr. Kroon has received personal compensation for serving as an employee of Annexon Biosciences. Dr. Kroon has stock in Annexon Biosciences.
-
Zhahirul Islam has nothing to disclose.
-
Dr. Navarro has nothing to disclose.
-
Prof. Azad has nothing to disclose.
-
Dr. Morrison has received personal compensation for serving as an employee of Alector. Dr. Morrison has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG . Dr. Morrison has stock in Alector. Dr. Morrison has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Pulkstenis has received personal compensation for serving as an employee of Annexon Biosciences. Dr. Pulkstenis has stock in Annexon Biosciences. Dr. Pulkstenis has stock in AbbVie.
-
Author has nothing to disclose